BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a sell rating to a strong sell rating in a report released on Wednesday morning.

A number of other equities research analysts also recently weighed in on MRUS. Royal Bank of Canada restated a buy rating and issued a $28.00 target price on shares of Merus in a research report on Wednesday, October 18th. Jefferies Group restated a buy rating and issued a $30.00 target price on shares of Merus in a research report on Thursday, October 26th. Wedbush restated an outperform rating and issued a $32.00 target price on shares of Merus in a research report on Friday, January 12th. Finally, Zacks Investment Research upgraded Merus from a sell rating to a hold rating in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Merus has a consensus rating of Hold and an average price target of $30.25.

Shares of Merus (NASDAQ:MRUS) traded up $1.29 during midday trading on Wednesday, hitting $17.79. The stock had a trading volume of 44,100 shares, compared to its average volume of 27,929. The firm has a market capitalization of $319.96, a P/E ratio of -3.25 and a beta of -0.94. Merus has a fifty-two week low of $13.23 and a fifty-two week high of $33.63.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, November 30th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.26). Merus had a negative return on equity of 119.36% and a negative net margin of 809.20%. analysts forecast that Merus will post -4.02 earnings per share for the current year.

An institutional investor recently bought a new position in Merus stock. Bain Capital Public Equity Management LLC purchased a new stake in Merus NV (NASDAQ:MRUS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 196,090 shares of the biotechnology company’s stock, valued at approximately $8,297,000. Bain Capital Public Equity Management LLC owned approximately 1.01% of Merus as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 29.36% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/15/merus-mrus-cut-to-strong-sell-at-bidaskclub.html.

About Merus

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.